Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Basic) (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EPS (Basic) for 16 consecutive years, with $0.22 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 115.83% year-over-year to $0.22, compared with a TTM value of $1.6 through Dec 2025, up 131.01%, and an annual FY2025 reading of -$0.01, up 99.8% over the prior year.
  • EPS (Basic) was $0.22 for Q4 2025 at Arrowhead Pharmaceuticals, up from -$0.14 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.78 in Q1 2025 and bottomed at -$1.39 in Q4 2024.
  • Average EPS (Basic) over 5 years is -$0.48, with a median of -$0.64 recorded in 2021.
  • The sharpest move saw EPS (Basic) crashed 321.74% in 2024, then skyrocketed 372.55% in 2025.
  • Year by year, EPS (Basic) stood at -$0.6 in 2021, then soared by 35.0% to -$0.39 in 2022, then tumbled by 217.95% to -$1.24 in 2023, then decreased by 12.1% to -$1.39 in 2024, then surged by 115.83% to $0.22 in 2025.
  • Business Quant data shows EPS (Basic) for ARWR at $0.22 in Q4 2025, -$0.14 in Q3 2025, and -$1.26 in Q2 2025.